CDPHP created the “Inside Look: A Call for Rx Transparency” website in order to educate consumers about drug costs, and motivate people to price drugs in a more rational fashion, said John Bennett, MD, FACC, FACP, president and CEO of CDPHP.
CDPHP created the “Inside Look: A Call for Rx Transparency” website in order to educate consumers about drug costs, and motivate people to price drugs in a more rational fashion, said John Bennett, MD, FACC, FACP, president and CEO of CDPHP.
Transcript (modified)
Why was the Inside Look: A Call for Rx Transparency website created and how does it benefit consumers?
We think it’s very important at this point that consumers be educated around the real problems around drug costs. And the real problems are the price of the drugs. We have some very effective and exciting medications which can change people’s lives, and save their lives in many cases. But these drugs are useless if no one can afford them.
And so we feel that the first step is educating our consumers as to what those real issues are and we believe in transparency in drug pricing. We believe that people need to come clean, that the pharmaceutical industry, in particular, needs to come clean and show what their costs of production really are so that we can get to a much more rational pricing of drugs, as opposed to the pure profit-taking that we have today.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More